Goldman keeps Buy rating for Lonza Group stock

Published on 10/07/2026 at 09:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Goldman's target is CHF 680.00 dated October 1, 2026. Lonza Group stock costs EUR 613.50 on October 7, 2026 after EUR 613.10.

Modernes Biotech-Produktionsgebäude mit Glas-Beton-Fassade, minimalistisch und funktional — Lonza CH0013841017 modernes Biotech Werk mit Glas Beton Fassade sauber und funktional, Illustration mit AI erstellt.

Lonza Group (ISIN CH0013841017) was trading at EUR 613.50 at Lang & Schwarz on October 7, 2026 at 9:12 a.m. CEST, up 0.07 percent from the prior close of EUR 613.10. The latest analyst signal came from Markets Insider on October 1, 2026, which reported that Goldman Sachs maintained a Buy rating and a CHF 680.00 price target.

Goldman holds its CHF 680 target

Goldman's target is below the CHF 730.00 target that Barclays maintained in a report dated September 28, 2026, according to Markets Insider. The two ratings keep the analyst backdrop positive, but the different targets point to a wider range of valuation assumptions around Lonza's growth and investment cycle.

The same report stated that Lonza generated CHF 3.37 billion in quarterly revenue and CHF 591.00 million in net profit for the quarter ended June 30, 2026, compared with CHF 3.03 billion of revenue and CHF 426.00 million of net profit a year earlier. That represents revenue growth of 11.22 percent and net profit growth of 38.73 percent on the figures reported by Markets Insider.

First-half growth meets higher margins

Lonza's half-year 2026 earnings call reported sales of CHF 3.40 billion, up 16.00 percent at constant exchange rates from the first half of 2025. Core EBITDA reached CHF 1.20 billion, an increase of 27.40 percent, while the Core EBITDA margin rose 4.40 percentage points to 34.80 percent, according to Yahoo Finance.

Management upgraded the full-year 2026 Core EBITDA margin outlook to 33.00 percent to 34.00 percent and reaffirmed constant-exchange-rate sales growth of 11.00 percent to 12.00 percent. The contrast matters: first-half growth was strong, while management expects more normalized second-half growth in Advanced Synthesis as the prior-year comparison becomes tougher.

Stock stays near the Swiss listing

Lonza is listed on the SIX Swiss Exchange under ticker LONN, and its business is classified as biotechnology. The company's strategy is increasingly centered on contract development and manufacturing, with investments in biologics, advanced synthesis and specialized modalities.

At Lang & Schwarz, the euro quote was EUR 613.50 on October 7, 2026 at 9:12 a.m. CEST, plus 0.07 percent versus the prior close of EUR 613.10. The further course of trading is shown by the continuously updated real-time quote of Lonza Group stock.